Literature DB >> 21826022

Cardiovascular manifestations of phaeochromocytoma.

Aleksander Prejbisz1, Jacques W M Lenders, Graeme Eisenhofer, Andrzej Januszewicz.   

Abstract

Clinical expression of phaeochromocytoma may involve numerous cardiovascular manifestations, but usually presents as sustained or paroxysmal hypertension associated with other signs and symptoms of catecholamine excess. Most of the life-threatening cardiovascular manifestations of phaeochromocytoma, such as hypertensive emergencies, result from a rapid and massive release of catecholamines from the tumour. More rarely, patients with phaeochromocytoma present with low blood pressure or even shock that may then precede multisystem crisis. Sinus tachycardia, with palpitations as the presenting symptom, is the most prevalent abnormality of cardiac rhythm in phaeochromocytoma, but tumours can also be associated with more serious ventricular arrhythmias or conduction disturbances. Reversible dilated or hypertrophic cardiomyopathy are well established cardiac manifestations of phaeochromocytoma, with more recent attention to an increasing number of cases with Takotsubo cardiomyopathy. This review provides an update on the cause, clinical presentation and treatment of the cardiovascular manifestations of phaeochromocytoma. As the cardiovascular complications of phaeochromocytoma can be life-threatening, all patients who present with manifestations that even remotely suggest excessive catecholamine secretion should be screened for the disease.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21826022     DOI: 10.1097/HJH.0b013e32834a4ce9

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  77 in total

1.  Uncommon presentation, rare complication and previously undescribed oncologic association of pheochromocytoma; the great masquerader.

Authors:  David Lawrence; Kevan Salimian; Thorsten Leucker; Seth Martin
Journal:  BMJ Case Rep       Date:  2018-04-05

2.  Rare cause of ventricular tachycardia: Pheochromocytoma.

Authors:  Joanna Delekta; Sam Riahi; Ole Eschen
Journal:  J Cardiol Cases       Date:  2014-11-14

3.  An atypical presentation of acute coronary syndrome.

Authors:  Amir Solomonica; Shahar Lavi; Tawfiq Choudhury; Rodrigo Bagur
Journal:  J Thorac Dis       Date:  2018-08       Impact factor: 2.895

4.  Pheochromocytoma presenting as acute decompensated heart failure reversed with medical therapy.

Authors:  Christopher M Mulla; Paul Ellis Marik
Journal:  BMJ Case Rep       Date:  2012-07-19

5.  The evaluation and treatment of endocrine forms of hypertension.

Authors:  Alejandro Velasco; Wanpen Vongpatanasin
Journal:  Curr Cardiol Rep       Date:  2014-09       Impact factor: 2.931

6.  Pheochromocytoma - update on disease management.

Authors:  Roland Därr; Jacques W M Lenders; Lorenz C Hofbauer; Bernd Naumann; Stefan R Bornstein; Graeme Eisenhofer
Journal:  Ther Adv Endocrinol Metab       Date:  2012-02       Impact factor: 3.565

Review 7.  Pathophysiology and Acute Management of Tachyarrhythmias in Pheochromocytoma: JACC Review Topic of the Week.

Authors:  Matthew A Nazari; Jared S Rosenblum; Mark C Haigney; Douglas R Rosing; Karel Pacak
Journal:  J Am Coll Cardiol       Date:  2020-07-28       Impact factor: 24.094

8.  Heart combined with adrenal multiple pheochromocytomas.

Authors:  Su-Hong Zhao; Shuang Liang; Jing Luo; Hong-Dan Mo; Yu Jiang; Mao-Mao Zhang; Jie Yuan
Journal:  J Nucl Cardiol       Date:  2017-06-07       Impact factor: 5.952

9.  Recurrence of non-cardiogenic pulmonary edema and sustained hypotension shock in cystic pheochromocytoma.

Authors:  Jin Dai; Shen-Jie Chen; Bing-Sheng Yang; Shu-Min Lü; Min Zhu; Yi-Fei Xu; Jie Chen; Hong-Wen Cai; Wei Mao
Journal:  J Zhejiang Univ Sci B       Date:  2017-05       Impact factor: 3.066

10.  Embolisation of pheochromocytoma to stabilise and wean a patient in cardiogenic shock from emergency extracorporeal life support.

Authors:  Helle Vagner; Thomas Morris Hey; Bo Elle; Marianne Kjær Jensen
Journal:  BMJ Case Rep       Date:  2015-03-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.